1 / 7

Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis, 2017 - Clinical Trials, Designation & Collaboration

Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis, 2017 - Clinical Trials, Designation & Collaboration

NidhiNehani
Download Presentation

Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis, 2017 - Clinical Trials, Designation & Collaboration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Amyotrophic Lateral Sclerosis (ALS) Pipeline Projects Vast Growth Ahead

  2. Amyotrophic Lateral Sclerosis According to a new research report “Amyotrophic Lateral Sclerosis Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Amyotrophic lateral sclerosis currently exhibits a pipeline with 72 drug candidates. Browse Report Description at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis

  3. Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis pipeline offers novel therapeutic targets for the treatment of Amyotrophic lateral sclerosis The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 72 drug candidates in different stages of development. Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region. The progressive degeneration of neurons from brain to the spinal cord and spinal cord to the whole body can ultimately lead to their death. Amyotrophic lateral sclerosis is classified into two types, namely, sporadic and familial. Approximately 90% to 95% of the patients suffering from the disease in the U.S. are experience the sporadic.

  4. Amyotrophic Lateral Sclerosis Insights on pipeline segments According to the route of administration analysis, most of the drug candidates are being developed to be administered by oral route. NurOwn technology platform for Amyotrophic Lateral Sclerosis drug development NurOwn is a cell therapy platform that builds on the enormous research effort that has gone into developing mesenchymal stem cells (MSCs) as a treatment for human diseases.

  5. Amyotrophic Lateral Sclerosis Major companies collaborate for the development of Amyotrophic Lateral Sclerosis Pipeline The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan. Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, and others.

  6. Amyotrophic Lateral Sclerosis Download report sample at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis/report-sample

  7. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related